0212 PDev QTs
BioCentury & Getty Images

Product Development

Feb. 12 Quick Takes: G1’s first approval is first in class; plus Seagen, Denali, Roche and Takeda

Feb 13, 2021 | 1:10 AM GMT

Shares of G1 Therapeutics Inc. (NASDAQ:GTHX) rose 20% to $37.15 in after-hours trading

Read the full 436 word article

How to gain access

Continue reading with a
two-week free trial.